13 February 2024

The Lung Cancer Policy Network has published our 2023 in review: building the evidence base report, detailing what the Network and its members have achieved over the past year. Throughout our outputs and activities in 2023, we sought to demonstrate the breadth of evidence there is to support reducing lung cancer mortality rates.

Over the past year, our global Network membership has grown in number, with the Network now representing 24 countries across 6 continents. The scope of Network member knowledge has been key in developing impactful and practical outputs for policy engagement, and collaboration between the Network and its members facilitates for the delivery of resources that evidence-based and consensus-driven.

We hope that this report will be useful for Network funders, members and the general public in understanding the impact of Network activities.

As we look ahead to 2024, we will still be seeking to grow the Network membership and collaborate with organisations that share our vision of making lung cancer a policy priority. In particular, we will be focusing on driving policy action this year.

Download the report

Share

Recent news

Blog

Meet our members: Ebba Hallersjö Hult

Meet our members: Ebba Hallersjö Hult

We speak to Ebba Hallersjö Hult, Co-founder and Head of Vision Zero Cancer, a mission-oriented innovation hub coordinated by Stockholm School of Economics Institute for Research, Sweden.

Case study

Lung cancer screening in Croatia: leading the way for earlier detection in Europe

Lung cancer screening in Croatia: leading the way for earlier detection in Europe

We explore key considerations for the success of the lung cancer screening programme in Croatia, discussing the pivotal role that integrated technology and reimbursement for primary care providers have played.

Blog

Reflections on 2023

Reflections on 2023

This year, the Network has focused on building an extensive evidence base that underpins key policy goals which look at addressing the global burden of lung cancer.